Novo Nordisk shares drop 10% after cardiovascular trial disappoints
The decline follows a disappointing readout in a cardiovascular outcomes programme, adding to pressure on the Danish drugmaker's pipeline narrative.
TR
By Tom Reyes · Markets Editor
Jul 31 03:00 ETSource: Financial Times
The wire
- 01Novo Nordisk shares fell 10% after a cardiovascular drug trial produced disappointing results, the Financial Times reported.
- 02Novo's valuation is closely tied to its peptide franchise, so pipeline setbacks feed directly into investor views of its obesity and cardiometabolic strategy.
- 03Detailed trial data, endpoints and any regulatory implications were not available in the report; readers should wait for the full disclosure.
From the source
Read at ft.comNovo Nordisk shares drop 10% after cardiovascular drug trial disappoints